Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.

Cognitive decline, Alzheimer's disease (AD) and other causes are major public health problems worldwide. With changing demographics, the number of persons with dementia will increase rapidly. The treatment and prevention of AD and other dementias, therefore, is an urgent unmet need. There have been considerable advances in understanding the biology of many age-related disorders that cause dementia. Gains in understanding AD have led to the development of ante-mortem biomarkers of traditional neuropathology and the conduct of several phase III interventions in the amyloid-β cascade early in the disease process. Many other intervention strategies are in various stages of development. However, efforts to date have met with limited success. A recent National Institute on Aging Research Summit led to a number of requests for applications. One was to establish multi-disciplinary teams of investigators who use systems biology approaches and stem cell technology to identify a new generation of AD targets. We were recently awarded one of three such grants to build a pipeline that integrates epidemiology, systems biology, and stem cell technology to discover and validate novel therapeutic targets and lead compounds for AD treatment and prevention. Here we describe the two cohorts that provide the data and biospecimens being exploited for our pipeline and describe the available unique datasets. Second, we present evidence in support of a chronic disease model of AD that informs our choice of phenotypes as the target outcome. Third, we provide an overview of our approach. Finally, we present the details of our planned drug discovery pipeline.

[1]  Sarah A. Chau,et al.  Current and Emerging Drug Treatment Options for Alzheimer’s Disease , 2011, Drugs.

[2]  R. Green,et al.  Extended results of the Alzheimer’s disease anti-inflammatory prevention trial , 2011, Alzheimer's & Dementia.

[3]  Yan Li,et al.  Confounding in the estimation of mediation effects , 2007, Comput. Stat. Data Anal..

[4]  U. Halsband,et al.  Motor learning in man: A review of functional and clinical studies , 2006, Journal of Physiology-Paris.

[5]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[6]  G. Perry,et al.  Oxidative stress in Alzheimer disease: A possibility for prevention , 2010, Neuropharmacology.

[7]  Zachary D. Smith,et al.  Unbiased Reconstruction of a Mammalian Transcriptional Network Mediating Pathogen Responses , 2009 .

[8]  S. Leurgans,et al.  Cerebral amyloid angiopathy pathology and cognitive domains in older persons , 2011, Annals of neurology.

[9]  M. Albert,et al.  Exploring candidate gene associations with neuropsychological performance , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[10]  D. Bennett,et al.  An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. , 2013, JAMA neurology.

[11]  T. Montine,et al.  Pathologic Correlates of Dementia in Individuals with Lewy Body Disease , 2010, Brain pathology.

[12]  D. Bennett,et al.  Functional connectivity networks associated with chronic musculoskeletal pain in old age , 2013, International journal of geriatric psychiatry.

[13]  David A Bennett,et al.  Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. , 2012, Archives of general psychiatry.

[14]  M. Weiner,et al.  A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium , 2008, Alzheimer's & Dementia.

[15]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[16]  S. Leurgans,et al.  APOE ε4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death. , 2013, Psychology and aging.

[17]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[18]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[19]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[20]  B. Liu,et al.  Amyloid-β Immunotherapy for Alzheimers Disease , 2010 .

[21]  D. Bennett,et al.  Correlates of Susceptibility to Scams in Older Adults Without Dementia , 2014, Journal of elder abuse & neglect.

[22]  D. Dickson,et al.  TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease , 2007, Annals of neurology.

[23]  W. Honer,et al.  Brain tocopherols related to Alzheimer's disease neuropathology in humans , 2015, Alzheimer's & Dementia.

[24]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[25]  D. Bennett,et al.  Association of Parkinson disease risk loci with mild parkinsonian signs in older persons. , 2014, JAMA neurology.

[26]  C. Carter,et al.  Anterior cingulate cortex and conflict detection: An update of theory and data , 2007, Cognitive, affective & behavioral neuroscience.

[27]  L. Feuk,et al.  Sequence variants of IDE are associated with the extent of β-amyloid deposition in the Alzheimer's disease brain , 2005, Neurobiology of Aging.

[28]  Bart Rypma,et al.  Prefrontal modulation of working memory performance in brain injury and disease , 2006, Human brain mapping.

[29]  K. Mirnics,et al.  Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex. , 2006, Progress in brain research.

[30]  R. Mayeux,et al.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants , 2011, Neurobiology of Aging.

[31]  D. Bennett,et al.  Alternative Approaches in Gene Discovery and Characterization in Alzheimer’s Disease , 2013, Current Genetic Medicine Reports.

[32]  J. Shulman,et al.  Functional screening of Alzheimer pathology genome-wide association signals in Drosophila. , 2011, American journal of human genetics.

[33]  D. Bennett,et al.  Association of cognition with temporal discounting in community based older persons , 2012, BMC Geriatrics.

[34]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[35]  D. Bennett,et al.  Chronic distress and incidence of mild cognitive impairment , 2007, Neurology.

[36]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  K. Blennow,et al.  Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study , 2012, The Lancet Neurology.

[38]  D. Bennett,et al.  Temporal Discounting Is Associated with an Increased Risk of Mortality among Community-Based Older Persons without Dementia , 2013, PloS one.

[39]  S. Leurgans,et al.  The CETP I405V polymorphism is associated with an increased risk of Alzheimer’s disease , 2012, Aging cell.

[40]  David A. Bennett,et al.  Internet use and decision making in community-based older adults , 2013, Front. Psychol..

[41]  H. Fillit,et al.  Beyond amyloid: the future of therapeutics for Alzheimer's disease. , 2012, Advances in pharmacology.

[42]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[43]  C. Bell,et al.  Risk factors and preventive interventions for Alzheimer disease: state of the science. , 2011, Archives of neurology.

[44]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[45]  J. Morris,et al.  Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. , 2005, Archives of neurology.

[46]  N. Friedman,et al.  Comprehensive comparative analysis of strand-specific RNA sequencing methods , 2010, Nature Methods.

[47]  V. Perry Contribution of systemic inflammation to chronic neurodegeneration , 2010, Acta Neuropathologica.

[48]  Jean-François Dartigues,et al.  The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. , 2005, Brain : a journal of neurology.

[49]  E. Hoshi Functional specialization within the dorsolateral prefrontal cortex: A review of anatomical and physiological studies of non-human primates , 2006, Neuroscience Research.

[50]  D. Bennett,et al.  Diabetes is related to cerebral infarction but not to AD pathology in older persons , 2006, Neurology.

[51]  S. Leurgans,et al.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. , 2012, Brain : a journal of neurology.

[52]  David A Bennett,et al.  Estimation of the mediation effect with a binary mediator , 2006, Statistics in medicine.

[53]  D. Bennett,et al.  Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease , 2010, PloS one.

[54]  J. Schneider,et al.  Individual differences in rates of change in cognitive abilities of older persons. , 2002, Psychology and aging.

[55]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[56]  John L. Robinson,et al.  Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases , 2007, Acta Neuropathologica.

[57]  J B Langbaum Correction: Ushering in the study and treatment of preclinical Alzheimer disease , 2013 .

[58]  Ronald J. Moore,et al.  Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.

[59]  J. Rodda,et al.  Cholinesterase inhibitors and memantine for symptomatic treatment of dementia , 2012, BMJ : British Medical Journal.

[60]  R. Haier,et al.  The Parieto-Frontal Integration Theory (P-FIT) of intelligence: Converging neuroimaging evidence , 2007, Behavioral and Brain Sciences.

[61]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[62]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[63]  J. Hardy,et al.  Twenty years of Alzheimer’s disease‐causing mutations , 2012, Journal of neurochemistry.

[64]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[65]  W. Klein Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? , 2012, Journal of Alzheimer's disease : JAD.

[66]  K. Blennow,et al.  Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.

[67]  D. Bennett,et al.  Relation of neuropathology with cognitive decline among older persons without dementia , 2013, Front. Aging Neurosci..

[68]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[69]  D. Bennett,et al.  Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[70]  Kristine Yaffe,et al.  Promising strategies for the prevention of dementia. , 2009, Archives of neurology.

[71]  C. Ranganath,et al.  Dorsolateral Prefrontal Cortex Promotes Long-Term Memory Formation through Its Role in Working Memory Organization , 2006, The Journal of Neuroscience.

[72]  David A. Bennett,et al.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles , 2009, Neurology.

[73]  P. Raina,et al.  Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.

[74]  D. Bennett,et al.  Apolipoprotein E and Change in Episodic Memory in Blacks and Whites , 2013, Neuroepidemiology.

[75]  D. Bennett,et al.  Ventromedial PFC, parahippocampal, and cerebellar connectivity are associated with temporal discounting in old age , 2013, Experimental Gerontology.

[76]  A. Fleisher,et al.  Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.

[77]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[78]  Jacob T. Robinson,et al.  Systematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits , 2011, Cell.

[79]  David A Bennett,et al.  Brain amyloid-β oligomers in ageing and Alzheimer's disease. , 2013, Brain : a journal of neurology.

[80]  R. Lipton,et al.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.

[81]  H. Amièva,et al.  Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms , 2008, Annals of neurology.

[82]  Z. Walker,et al.  Identification of biomarkers in Lewy-body disorders. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[83]  Lars Malmström,et al.  Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes , 2012, Nature Communications.

[84]  D. Bennett,et al.  Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. , 2013, JAMA neurology.

[85]  L. Ferrucci,et al.  Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). , 2009, Journal of Alzheimer's disease : JAD.

[86]  William J. Jagust,et al.  Brain imaging in the study of Alzheimer's disease , 2012, NeuroImage.

[87]  K. Zahs,et al.  Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.

[88]  Jeffrey M. Hausdorff,et al.  Associations between Quantitative Mobility Measures Derived from Components of Conventional Mobility Testing and Parkinsonian Gait in Older Adults , 2014, PloS one.

[89]  L. Launer,et al.  Relevance of Cardiovascular Risk Factors and Ischemic Cerebrovascular Disease to the Pathogenesis of Alzheimer Disease: A Review of Accrued Findings From the Honolulu-Asia Aging Study , 2006, Alzheimer disease and associated disorders.

[90]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[91]  D. Bennett,et al.  TDP-43 pathology, cognitive decline, and dementia in old age. , 2013, JAMA neurology.

[92]  R. Castellani,et al.  Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.

[93]  Angela Cacace,et al.  Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease , 2013, Alzheimer's & Dementia.

[94]  J. Suhy,et al.  Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab , 2011, Alzheimer's & Dementia.

[95]  M. Iacoboni Neural mechanisms of imitation , 2005, Current Opinion in Neurobiology.

[96]  Ottavio Arancio,et al.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? , 2012, The Biochemical journal.

[97]  Jason J. Corneveaux,et al.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.

[98]  Jeffrey M. Hausdorff,et al.  Using a Body-Fixed Sensor to Identify Subclinical Gait Difficulties in Older Adults with IADL Disability: Maximizing the Output of the Timed Up and Go , 2013, PloS one.

[99]  A. Myers,et al.  A common polymorphism near PER1 and the timing of human behavioral rhythms , 2012, Annals of neurology.

[100]  D. Bennett,et al.  Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women , 2014, Neurology.

[101]  David A. Bennett,et al.  Decision Rules Guiding the Clinical Diagnosis of Alzheimer’s Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort Study , 2006, Neuroepidemiology.

[102]  P. Tariot,et al.  A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.

[103]  Jessica C. Payne-Murphy,et al.  Trajectory of mild cognitive impairment onset , 2008, Journal of the International Neuropsychological Society.

[104]  R. Berman,et al.  Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. , 2012, Clinical therapeutics.

[105]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[106]  J. Schneider,et al.  Much of late life cognitive decline is not due to common neurodegenerative pathologies , 2013, Annals of neurology.

[107]  S. Leurgans,et al.  Disentangling the effects of age and APOE on neuropathology and late life cognitive decline , 2014, Neurobiology of Aging.

[108]  S. Leurgans,et al.  Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. , 2011, Archives of neurology.

[109]  Jason J. Corneveaux,et al.  Genetic susceptibility for Alzheimer disease neuritic plaque pathology. , 2013, JAMA neurology.

[110]  J. Schneider,et al.  Overview and findings from the rush Memory and Aging Project. , 2012, Current Alzheimer research.

[111]  J. Morris,et al.  Longitudinal study of the transition from healthy aging to Alzheimer disease. , 2009, Archives of neurology.

[112]  Ronald J. Moore,et al.  Enhanced Sensitivity for Selected Reaction Monitoring Mass Spectrometry-based Targeted Proteomics Using a Dual Stage Electrodynamic Ion Funnel Interface* , 2010, Molecular & Cellular Proteomics.

[113]  Scott A Huettel,et al.  Modulation of prefrontal cortex activity by information toward a decision rule , 2004, Neuroreport.

[114]  S. Black,et al.  Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[115]  Véronique D. Bohbot,et al.  Spatial navigational strategies correlate with gray matter in the hippocampus of healthy older adults tested in a virtual maze , 2013, Front. Ag. Neurosci..

[116]  Lars Bäckman,et al.  Longitudinal Trajectories of Cognitive Change in Preclinical Alzheimer's Disease: A Growth Mixture Modeling Analysis , 2007, Cortex.

[117]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[118]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[119]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[120]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[121]  C. Ballard,et al.  Treatment of Dementia with Lewy Bodies and Parkinson’s Disease Dementia , 2011, Drugs & aging.

[122]  T. Wyss-Coray,et al.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. , 2012, Cold Spring Harbor perspectives in medicine.

[123]  W. Markesbery,et al.  Characterization of Japanese-American men with a single neocortical AD lesion type , 2008, Neurobiology of Aging.

[124]  M. Petrides,et al.  Selective involvement of the mid-dorsolateral prefrontal cortex in the coding of the serial order of visual stimuli in working memory , 2007, Proceedings of the National Academy of Sciences.

[125]  D. Bennett,et al.  Principal components methods for narrow‐sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[126]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[127]  Robert C. Green,et al.  Genome-wide association study of the rate of cognitive decline in Alzheimer's disease , 2014, Alzheimer's & Dementia.

[128]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[129]  R. Green,et al.  The Framingham Brain Donation Program: neuropathology along the cognitive continuum. , 2012, Current Alzheimer research.

[130]  Jason J. Corneveaux,et al.  A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. , 2012, Human molecular genetics.

[131]  Anne Corbett,et al.  New and emerging treatments for Alzheimer’s disease , 2012, Expert review of neurotherapeutics.

[132]  R. Sperling The potential of functional MRI as a biomarker in early Alzheimer's disease , 2011, Neurobiology of Aging.

[133]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[134]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[135]  Janna H. Neltner,et al.  GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology , 2012, Neurology.

[136]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[137]  David A. Bennett,et al.  Life-span cognitive activity, neuropathologic burden, and cognitive aging , 2013, Neurology.

[138]  Ramon Diaz-Arrastia,et al.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. , 2008, JAMA.

[139]  Jeffrey L. Cummings,et al.  Biomarkers in Alzheimer's disease drug development , 2011, Alzheimer's & Dementia.

[140]  S. Leurgans,et al.  Neurodegenerative basis of age-related cognitive decline , 2010, Neurology.

[141]  Sivaraman Dandapani,et al.  Current strategies for diversity-oriented synthesis. , 2010, Current opinion in chemical biology.

[142]  H. Hendrie,et al.  Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature , 2009, Alzheimer disease and associated disorders.

[143]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[144]  Rogier B. Mars,et al.  Dorsolateral Prefrontal Cortex, Working Memory, and Prospective Coding for Action , 2007, The Journal of Neuroscience.

[145]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Eric M Reiman,et al.  Functional Links Between Aβ Toxicity, Endocytic Trafficking, and Alzheimer’s Disease Risk Factors in Yeast , 2011, Science.

[147]  Lukas N. Mueller,et al.  Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics , 2009, Cell.

[148]  Leslie G. Ungerleider,et al.  Involvement of human left dorsolateral prefrontal cortex in perceptual decision making is independent of response modality , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[149]  D. Bennett,et al.  Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. , 2012, American journal of human genetics.

[150]  D. Bennett,et al.  Cognitive decline impairs financial and health literacy among community-based older persons without dementia. , 2013, Psychology and aging.

[151]  B. Keenan,et al.  An exploration of a functional unit of DNA methylation in the aging brain , 2013, Alzheimer's & Dementia.

[152]  L. Nyberg,et al.  Common fronto-parietal activity in attention, memory, and consciousness: Shared demands on integration? , 2005, Consciousness and Cognition.

[153]  J. Schneider,et al.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. , 2004, Archives of neurology.

[154]  W. Tsai,et al.  A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics , 2008, Clinical trials.

[155]  S. Bodovitz,et al.  The neural correlate of consciousness. , 2008, Journal of theoretical biology.

[156]  James R. Burke,et al.  Systematic Review: Factors Associated With Risk for and Possible Prevention of Cognitive Decline in Later Life , 2010, Annals of Internal Medicine.

[157]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[158]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[159]  S. Resnick,et al.  Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohort , 2010, Annals of neurology.

[160]  D. Bennett,et al.  Risk Aversion is Associated with Decision Making among Community-Based Older Persons , 2012, Front. Psychology.

[161]  David A Bennett,et al.  The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. , 2002, Archives of neurology.

[162]  Owen Carmichael,et al.  Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative , 2010, Alzheimer's & Dementia.

[163]  D. A. Bennett,et al.  Natural history of mild cognitive impairment in older persons , 2002, Neurology.

[164]  M. Sabbagh,et al.  Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease , 2013, Drugs & Aging.

[165]  Jagan A. Pillai,et al.  Clinical trials in predementia stages of Alzheimer disease. , 2013, The Medical clinics of North America.

[166]  David A Bennett,et al.  CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. , 2014, Human molecular genetics.

[167]  F. M. Mottaghy,et al.  Interfering with working memory in humans , 2006, Neuroscience.

[168]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[169]  W. Markesbery,et al.  AD brain pathology: Vascular origins? Results from the HAAS autopsy study , 2008, Neurobiology of Aging.

[170]  Richard D. Smith,et al.  Advancing the sensitivity of selected reaction monitoring‐based targeted quantitative proteomics , 2012, Proteomics.

[171]  Richard J. Caselli,et al.  Ushering in the study and treatment of preclinical Alzheimer disease , 2013, Nature Reviews Neurology.

[172]  R. Durbin,et al.  Mapping Quality Scores Mapping Short Dna Sequencing Reads and Calling Variants Using P

, 2022 .

[173]  J. Schneider,et al.  Harm avoidance and cerebral infarction. , 2014, Neuropsychology.

[174]  D. Bennett,et al.  Association of brain pathology with the progression of frailty in older adults , 2013, Neurology.

[175]  E. Sigurdsson,et al.  Tau as a therapeutic target for Alzheimer's disease. , 2011, Current Alzheimer research.

[176]  R. Wilson,et al.  Relation of neuropathology to cognition in persons without cognitive impairment , 2012, Annals of neurology.

[177]  D. Bennett,et al.  Early and late life cognitive activity and cognitive systems in old age , 2005, Journal of the International Neuropsychological Society.

[178]  D. Holtzman,et al.  Alzheimer disease in 2020. , 2012, Cold Spring Harbor perspectives in medicine.

[179]  David A. Bennett,et al.  Poor Decision Making Is a Consequence of Cognitive Decline among Older Persons without Alzheimer’s Disease or Mild Cognitive Impairment , 2012, PloS one.

[180]  C. Ranganath,et al.  The Dorsolateral Prefrontal Cortex Contributes to Successful Relational Memory Encoding , 2007, The Journal of Neuroscience.

[181]  J. Schneider,et al.  Loneliness and risk of Alzheimer disease. , 2007, Archives of general psychiatry.

[182]  J. Morrison,et al.  Session II: Mechanisms of age-related cognitive change and targets for intervention: neural circuits, networks, and plasticity. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[183]  P. Worley,et al.  Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development , 2012, Neuropsychopharmacology.

[184]  D. Bennett,et al.  Emotional neglect in childhood and cerebral infarction in older age , 2012, Neurology.

[185]  M. Sapra,et al.  Anti-amyloid treatments in Alzheimer's disease. , 2009, Recent patents on CNS drug discovery.

[186]  Aviv Regev,et al.  Comprehensive comparative analysis of RNA sequencing methods for degraded or low input samples , 2013, Nature Methods.

[187]  A. Roses,et al.  Longitudinal modeling of cognitive aging and the TOMM40 effect , 2012, Alzheimer's & Dementia.

[188]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[189]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[190]  S. Sando,et al.  Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. , 2010, Parkinsonism & related disorders.

[191]  B. Domon,et al.  Selected reaction monitoring applied to proteomics. , 2011, Journal of mass spectrometry : JMS.

[192]  J. Cummings,et al.  Discovering new treatments for Alzheimer's disease by repurposing approved medications. , 2013, Current topics in medicinal chemistry.

[193]  David A. Bennett,et al.  The apolipoprotein E ε2 allele and decline in episodic memory , 2002 .

[194]  D. Bennett,et al.  Microvascular brain pathology and late-life motor impairment , 2013, Neurology.

[195]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[196]  D. Bennett,et al.  The influence of cognitive decline on well-being in old age. , 2013, Psychology and aging.

[197]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[198]  D. Bennett,et al.  Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology , 2012, The Journal of Neuroscience.